The size of the antibiotics market in the United States is estimated to be growing at a CAGR of 6.04% during the forecast period.
The increasing incidents of chronic and infectious diseases worldwide and the effectiveness of antibiotics in curing a wide range of bacterial infections have led to the rapid growth of the antibiotics market in the United States.
The increasing prevalence of bacterial infections, coupled with the need for newer and more effective antibiotics, drives the demand for advanced antibiotics. With urbanization and the destruction of natural habitats, climate change, and the evolution of ecosystems, infectious diseases are emerging. This places a heavy burden on developing economies. The growing threat of drug resistance and the shortage of new molecules lead to the development of combinatorial formulations.
Advances in generic drugs and the growing aging of the vulnerable population are also contributing to the overall growth of the U.S. antibiotics market. According to the 2019 United Nations Report on Population Aging, the world's population aged 60 and over was 982 million in 2019, more than double the number in 1985 when 396 million older people were in the world. Due to this, pharmaceutical and diagnostic companies are striving to develop new techniques that identify the cause of disease and treat it. However, some problems associated with antibiotics, such as antibiotic resistance and long and cumbersome regulatory procedures, limit the adoption of antibiotics in the global market.
The greatest risk is for patients living in poorer countries, where drug options are limited, strict government standards and regulations for bringing new drugs to market will hamper the rate of market growth over time.
The interdependence of the United States with other countries for active pharmaceutical ingredients for drug manufacturing will create a competitive market for lower prices and gaps between supply and demand in the future.
Impact of COVID-19 on the U.S. antibiotics market:
The COVID-19 pandemic has created havoc around the world. Almost all sectors have been affected by the pandemic positively or negatively. A decrease in the volume of patients in independent clinics and hospitals has forced doctors to turn to digital health technologies to keep their business going. Pharmaceutical and medical device companies have suffered huge losses as a result of the pandemic.
The disruption of supply and restrictions on importing active pharmaceutical ingredients (APIs) for the manufacture of essential antimicrobials has negatively impacted market opportunities. China, one of the biggest API providers, imposed lockdowns in the early months of the pandemic, leading to antibiotic shortages in various parts of the world, including the United States. Increased government efforts to prevent nosocomial infections (HAIs), catheters and ventilation-associated infections generate lucrative market opportunities in the years to come.
This research report on the U.S. antibiotics market has been segmented and sub-segmented based on the following categories.
By Action Mechanism:
By Drug Class:
Geographically, this region is expected to increase its market share in the future due to the increased adoption of antibiotics. According to the Centers for Disease Control and Prevention (CDC), in 2020, 8,950 new cases of tuberculosis (TB) were reported in the United States, which represents an incidence rate of 2.9 cases per 100,000 population.
The United States has the largest market share in the North American region because it has the highest antibiotic prescription rate in the North American region. The United States is one of the countries hardest hit by the COVID-19 epidemic. As a result, the demand for antibiotics to treat nosocomial infections caused by the COVID-19 virus has also increased in the United States. In addition, favorable government regulations such as the Generate Antibiotics Incentive Act (GAIN) stimulate research and development processes, providing several opportunities for many companies in the United States.
KEY MARKET PLAYERS:
A few of the leading companies operating in the U.S. antibiotics market profiled in this report are Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org